How might the current biotech funding environment impact CRDF's ability to finance CRDF-005 into 2027?

The current biotech funding environment presents both opportunities and challenges for companies like Cardiff Oncology (CRDF) as they aim to finance drug development programs such as CRDF-005 into 2027. A deep dive into CRDF's financial health and the broader market sentiment is crucial for understanding potential impacts.

Cardiff Oncology's Financial Position

Based on its most recent filings, Cardiff Oncology reported cash, cash equivalents, and marketable securities of $68.6 million as of June 30, 2025. The company anticipates this capital will fund its operations into the second quarter of 2026. This suggests that, without additional financing, CRDF's current runway falls short of the 2027 target mentioned for CRDF-005.

The net cash used in operating activities was $10.1 million for the three months ended June 30, 2025, and $20.2 million for the six months ended June 30, 2025. This burn rate indicates a need for further capital infusion to extend their operational runway beyond Q2 2026, especially if CRDF-005 progresses into more expensive later-stage trials.

Biotech Funding Environment

The broader biotech funding environment in 2025 has shown a mixed picture. While venture capital funding for early-stage biotechs remains somewhat robust for promising assets, public market access for clinical-stage companies has been more selective. Companies with clear clinical milestones, strong data, and differentiated assets are generally better positioned to attract capital through follow-on offerings or partnerships. However, a challenging macroeconomic climate can lead to tighter capital markets, increased investor scrutiny, and potentially dilutive financing terms for companies seeking to raise funds.

Impact on CRDF-005 Financing

Given CRDF's projected cash runway into Q2 2026, the company will likely need to secure additional financing within the next 6-12 months to fund CRDF-005's development into 2027. The ability to do so will heavily depend on:

• Clinical Progress of CRDF-005: Positive data readouts and achievement of clinical milestones for CRDF-005 would significantly enhance investor confidence and improve financing prospects.
• Market Conditions: A more favorable biotech market with increased investor appetite for risk would make fundraising easier and potentially less dilutive.
• Strategic Partnerships: Exploring collaborations or licensing agreements for CRDF-005 could provide non-dilutive funding and shared development costs.

Investors will be closely watching CRDF's upcoming clinical updates for CRDF-005 and any strategic moves to bolster its balance sheet.

Evaluate recent public market financing trends for oncology-focused biotech companies with similar market capitalizations and development stages.

The current public market financing environment for oncology-focused biotech companies in 2025 remains selective, with investors prioritizing companies demonstrating strong clinical data and clear pathways to commercialization. While capital is available, particularly for promising assets, the terms can be challenging, and early-stage companies often face increased scrutiny and potential dilution.

For clinical-stage oncology biotechs, the ability to secure financing is heavily influenced by their development stage and the perceived risk of their pipeline. Companies with late-stage assets and upcoming catalysts, such as Cogent Biosciences, have successfully accessed non-dilutive financing, with Cogent securing up to $400 million in debt financing in June 2025 to support its expected launch of bezuclastinib in 2026. Similarly, NANOBIOTIX, a late-clinical stage company, is actively pursuing non-dilutive financing to extend its cash runway beyond mid-2026, building on an amended licensing agreement that extended its cash visibility. These examples suggest that as assets de-risk, non-dilutive options become more viable.

However, dilutive equity raises remain a common tool for many clinical-stage biotechs. Xilio Therapeutics, a clinical-stage immuno-oncology company, priced a $50.0 million public offering in June 2025, which included pre-funded warrants and multiple series of warrants, indicating that such structures are still prevalent to attract investors. Purple Biotech Ltd., also focused on oncology therapeutic candidates, conducted a $6 million follow-on offering in September 2025, with potential for additional proceeds from warrants. These instances highlight that while capital is accessible, it often comes with terms that can lead to shareholder dilution.

Conversely, companies facing significant capital constraints, especially those in earlier clinical stages without clear near-term catalysts, may struggle. Portage Biotech, a clinical-stage immuno-oncology company, discontinued several trials in 2024 due to "ongoing capital constraints and the broader funding environment for early-stage biotechnology companies," and expressed "significant doubt about the Company’s ability to continue as a going concern". This underscores the harsh realities for companies unable to demonstrate sufficient progress or secure adequate funding. Oncolytics Biotech, a clinical-stage immunotherapy company, reported $14.6 million in cash as of June 30, 2025, projecting a runway through Q1 2026, and opted to terminate its "at-the-market" financing facilities, believing it had sufficient capital for critical milestones without immediate dilutive financing. This suggests that clinical progress can empower companies to avoid dilutive financing.

In summary, the public market for oncology biotechs in 2025 is characterized by a strong preference for de-risked assets, leading to more favorable non-dilutive options for late-stage programs. For earlier clinical-stage companies, dilutive equity offerings, often sweetened with warrants, are still primary funding mechanisms, but the ability to secure these depends heavily on clinical progress and investor confidence.

Compare Cardiff Oncology's (CRDF) quarterly net cash used in operating activities against a peer group of 3-5 clinical-stage oncology companies with similar market caps over the past four quarters to assess its relative cash burn rate.